Editor’s note: This is a developing news story. Please check back soon for updates.
Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity Biotechnology.
The phase 2b study evaluated the safety and efficacy of UBX1325 compared with aflibercept in patients with DME who previously underwent treatment but did not achieve optimal benefit. Fifty-two patients were randomly assigned 1:1 to receive either 10 µg UBX1325 or 2 mg aflibercept control